Company: HCTI
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026218
Chunk: 23

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 23
---
 divert our attention from operating our
company and result in a temporary inability to use the intellectual property subject to such claim. In addition, if we, our ecosystem
partners, and/or customers become liable to third parties for infringing their intellectual property rights, we could be required to pay
a substantial damage award and develop comparable non-infringing intellectual property, to obtain a license, or to cease providing the
content or services that contain the infringing intellectual property. We may be unable to develop a non-infringing intellectual property
or obtain a license on commercially reasonable terms, if at all.

We may not be able to protect our intellectual property rights throughout
the world.

Third parties may attempt to commercialize competitive
products or services in foreign countries where we do not have a trademark or copyright registration or where legal recourse may be limited.
This may have a significant commercial impact on our foreign business operations which we expect to expand.

Registration and enforcement of intellectual property
rights to our platforms and services in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability
may differ in certain countries, particularly developing countries. For example, Europe has a heightened requirement for patentability
of software inventions. Thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will
issue with claims that cover our products. In addition, the laws of some foreign countries do not protect intellectual property rights
to the same extent as laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other
third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States or from selling or importing products concerning our healthcare technology into the United States or other jurisdictions. Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and services and
further, may export otherwise infringing products and services to territories where we have patent protection, but enforcement on infringing
activities is inadequate. These products or services may compete with ours, and our patents or other intellectual property rights may
not be effective or sufficient to prevent them from competing.

17

Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents